Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 3 for:    chiva | France
Previous Study | Return to List | Next Study

Immunotherapy by Nivolumab for HIV+ Patients (CHIVA2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03304093
Recruitment Status : Unknown
Verified March 2020 by Intergroupe Francophone de Cancerologie Thoracique.
Recruitment status was:  Active, not recruiting
First Posted : October 6, 2017
Last Update Posted : February 10, 2021
ANRS, Emerging Infectious Diseases
Information provided by (Responsible Party):
Intergroupe Francophone de Cancerologie Thoracique

Brief Summary:
Two Phase III trials showed superiority in terms of efficacy and tolerance of nivolumab in second-line treatment compared to docetaxel in metastatic NSCLC in the general population, so it is important to evaluate this treatment in PLWHIV (Patient Living With HIV) in maximum security conditions, taking into account their specificities and complex underlying immunological status. As NSCLC in PLWHIV is a rare tumour, a phase 2 trial, using DCR (Disease Control Rate) data, would be able to recruit a sufficient number of patients, in a reasonable period of time, to provide a proof of concept of the safety and efficacy of nivolumab in this population. Therefore, we think that an open-label, one arm phase 2 trial, with a rapid accrual, would be currently a crucial approach and a window of opportunity to explore whether nivolumab could find its place in PLWHIV with NSCLC. Such a trial is typically a trial for an academic sponsor, experienced in PLWHIV with NSCLC, which previously showed its ability to recruit patients with such a rare disease as the IFCT did with the IFCT-1001 CHIVA trial, testing carboplatin plus pemetrexed followed by pemetrexed.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer Stage IIIB HIV/AIDS Drug: Nivolumab Injection Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Immunotherapy by Nivolumab After Prior Chemotherapy for HIV+ Patients With Advanced Non-small Cell Lung Cancer (NSCLC): IFCT-CHIVA2 Phase IIa Trial
Actual Study Start Date : October 19, 2017
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Nivolumab
Nivolumab 3mg/kg every 2 weeks
Drug: Nivolumab Injection
Nivolumab 3mg/kg every 2 weeks

Primary Outcome Measures :
  1. Disease Control Rate [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: 6 months and one year ]
    Time between the date of inclusion and the first date of documented progression or death due to any cause, whichever occurs first. Subjects who die without a reported progression will be considered to have progressed on the date of their death. Subjects who did not progress or die will be censored on the date of their last evaluable tumor assessment.

  2. Overall Survival [ Time Frame: 6 months and one year ]
    Time elapsed between the date of inclusion and death. Subjects who did not die will be censored on the last date a subject was known to be alive.

  3. Tolerance [ Time Frame: 8 weeks, 6 months and one year ]
    Adverse Events (AEs) grade (NCI-CTC 4.0)

  4. Responses rate according to tissue PD-L1 expression [ Time Frame: 8 weeks ]
  5. Quality of life measured by LCSS questionnaire [ Time Frame: After 2, 3, 5, 7 and 9 cycles (each cycle is 14 days) ]
  6. Duration of response [ Time Frame: 8 weeks, 6 months and one year ]
  7. impact on HIV control and immunological, other associated chronic infection susceptible of reactivation and potential occurrence of autoimmunity [ Time Frame: 8 weeks, 6 months and one year ]

Other Outcome Measures:
  1. Monitor HIV, CMV, EBV, HBV, HCV, HHV-8-specific T cell responses in PBMC [ Time Frame: Cycle 1, 2, 3, 9, 15, 27, 51 and end of treatment (each cycle is 14 days) ]
  2. Monitor the HIV reservoirs (HIV-DNA) and the residual HIV replication as well as EBV CMV, HBV, HCV, HHV-8 viral load [ Time Frame: Cycle 1, 2, 3, 9, 15, 27, 51 and end of treatment (each cycle is 14 days) ]
  3. Monitor T cell activation/ exhaustion/differentiation and immune check point expression [ Time Frame: Cycle 1, 2, 3, 9, 15, 27, 51 and end of treatment (each cycle is 14 days) ]
  4. Description of gene mutation that appear to be crucial for the response to immunotherapy or for adverse effects of immunotherapy [ Time Frame: Cycle 1, 2, 3, 9, 15, 27, 51 and end of treatment (each cycle is 14 days) ]
  5. Immune monitoring of adverse effects [ Time Frame: Cycle 1, 2, 3, 9, 15, 27, 51 and end of treatment (each cycle is 14 days) ]
  6. Describe the tumoral microenvironment of NSCLC before nivolumab exposure (CD4, CD8, CD3 infiltrate, PD-1, PD-L1 expression) [ Time Frame: At enrolment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥ 18 years old
  2. HIV1 or HIV2, regardless of CD4 cell count
  3. HIV Viral load <200 copies/mL
  4. Proven histologically and/or cytologically, stage IIIB-IV or metastatic relapse post-surgery non-small cell lung cancer (NSCLC)
  5. Disease recurrence or progression during/after at least one prior platinum doublet-based chemotherapy regimen for advanced or metastatic disease
  6. Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST 1.1 criteria
  7. Performance status (PS) 0, 1 or 2
  8. Written informed consent
  9. Patients must have adequate organ function: creatinine clearance > 40 mL/min (Cockcroft, MDRD or CKD-Epi formula or 24h Urine Calculate creatinine clearance from a 24h urine collection ), neutrophiles count > 1500/mm3; platelets > 100 000/mm3 ; hemoglobin > 9 g/dL; hepatic enzymes < 3N with total bilirubin ≤ 1.5 × ULN (upper limit of normal) except subjects with documented Gilbert's syndrome (≤ 5 × ULN) or liver metastasis, who must have a baseline total bilirubin ≤ 3.0 mg/dL
  10. Patients must receive appropriate care and treatment for HIV infection including ART when clinically indicated and subjects should be under the care of a physician experienced in HIV management. In case of recent introduction of cART and CD4 levels <50 cells/ml, inclusion will be possible provided subjects had at least 4 weeks of treatment prior to inclusion, to avoid clinical type IRIS (immune inflammatory syndrome reconstitution). All antiretroviral treatments are allowed.
  11. Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using such precautions for 6 months after the final dose of investigational product; cessation of contraception after this point should be discussed with the referent physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. They must also refrain from egg cell donation for 6 months after the final dose of investigational product. Men receiving nivolumab and who are sexually active with women of childbearing potential will be instructed to adhere to contraception (appendix I) for a period of 31 weeks after the last dose of nivolumab.
  12. Persons deprived of liberty could be eligible because the expected benefice (improvement of disease control rate) justifies the foreseeable risk (adverse reaction of nivolumab).

Exclusion Criteria:

  1. Concurrent malignancies requiring active intervention
  2. Active Infection
  3. Patient with known EGFR activating tumor mutation or known ALK or ROS1 gene rearrangement not treated with the appropriate targeted therapy.
  4. History of immunological events related to HIV: lymphoid interstitial pneumonitis (LIP), non-infectious uveitis, encephalitis and other manifestations of CD8 lymphocyte infiltration syndrome, HIV-associated nephropathy (HIVAN).
  5. Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  6. Active or history of inflammatory bowel disease (eg, diverticulitis, colitis, Crohn's, coeliac disease or other serious gastrointestinal chronic conditions associated with diarrhea). Note that diverticulosis is permitted.
  7. Symptomatic cerebral metastasis unless treated by brain radiotherapy which will be completed for at least 15 days before the beginning of the treatment; subjects with carcinomatous meningitis.
  8. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
  9. The last dose of prior chemotherapy or radiation therapy (with the exception of palliative radiotherapy) was received less than 3 weeks prior to inclusion;
  10. History of primary immunodeficiency, history of organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of inclusion or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy.
  11. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of inclusion. Intranasal/inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  12. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.
  13. Legally protected adults.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03304093

Show Show 18 study locations
Sponsors and Collaborators
Intergroupe Francophone de Cancerologie Thoracique
ANRS, Emerging Infectious Diseases
Layout table for investigator information
Principal Investigator: Armelle LAVOLE, MD APHP Hôpital Tenon
Principal Investigator: Jacques CADRANEL, MD, PhD APHP Hôpital Tenon
Layout table for additonal information
Responsible Party: Intergroupe Francophone de Cancerologie Thoracique Identifier: NCT03304093    
Other Study ID Numbers: IFCT-1602
First Posted: October 6, 2017    Key Record Dates
Last Update Posted: February 10, 2021
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Intergroupe Francophone de Cancerologie Thoracique:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action